Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQN1 | ISIN: US76029N1063 | Ticker-Symbol: 7R8
Tradegate
31.03.25
21:18 Uhr
8,800 Euro
-0,800
-8,33 %
1-Jahres-Chart
REPLIMUNE GROUP INC Chart 1 Jahr
5-Tage-Chart
REPLIMUNE GROUP INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,0009,05022:00
8,9009,15022:00

Aktuelle News zur REPLIMUNE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.03.Replimune Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
07.03.Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)146WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
► Artikel lesen
07.03.Replimune Group, Inc. - 8-K, Current Report2
12.02.Replimune Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
12.02.Replimune Group GAAP EPS of -$0.79 misses by $0.071
12.02.Replimune Group, Inc. - 10-Q, Quarterly Report1
12.02.Replimune Group, Inc. - 8-K, Current Report-
REPLIMUNE Aktie jetzt für 0€ handeln
07.02.Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)157WOBURN, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...
► Artikel lesen
22.01.Replimune Group, Inc. - 8-K, Current Report1
22.01.Replimune Group (NASDAQ:REPL) Stock Price Up 6% After Analyst Upgrade1
21.01.Replimune stock soars on FDA priority review for melanoma treatment3
21.01.Replimune-Aktie steigt nach FDA-Prioritätsprüfung für Melanom-Behandlung2
21.01.Replimune announces priority review for its melanoma treatment3
17.01.Replimune Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
14.01.Replimune Group (NASDAQ:REPL) Shares Down 6.6% - What's Next?4
10.01.Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)187WOBURN, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...
► Artikel lesen
20.12.24Replimune Group, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
26.11.24Replimune Prices Public Offering Of 6.923 Mln Common Shares At $13/Shr3
26.11.24Replimune prices $140M offering at $13 per share2
26.11.24Replimune Group Inc: Replimune Announces Pricing of Upsized Public Offering2
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1